Antiageing Developments: Past, Present and Future

Dear Colleagues,

Antiageing research is a broad field that encompasses a wide range of approaches, technologies, and products that slow or reverse ageing processes. This includes research on interventions that may delay or prevent age-related diseases, as well as efforts to improve physical and cognitive functioning in older adults. If we were to trace the developments in the field retrospectively, we would see that, in the past, antiageing research and development has primarily focused on developing treatments for age-related diseases and conditions, such as cardiovascular disease, cancer, and Alzheimer's disease. However, researchers have also explored the use of various nutrients, hormones, and other substances as potential antiageing interventions.

The field has expanded, and nowadays, we witness blooming antiageing research focused on the developing interventions for age-related diseases and conditions and understanding the underlying molecular and cellular processes that drive ageing. A growing area of research is the study of senolytic drugs, which selectively eliminate senescent cells. Another area of focus is the use of stem cells and regenerative medicine to repair or replace damaged tissues and organs. Some researchers are also exploring gene editing technologies, such as CRISPR, to modify the genetic basis of ageing.

The future will likely focus on developing interventions for age-related diseases and conditions. We expect the use of stem cells, gene-editing technologies, and other innovative approaches to repair or replace damaged tissues and organs to be fully established as a legitimate means of treatment. Advances have also been made in terms of unlocking the potential use of nanotechnologies, such as nanorobots, to repair or replace damaged cells or tissues at the molecular level.

We welcome the submission of research and review papers that describe the modern contemporary situation in antiageing research. The central focus will be on factors that drive ageing, including genetic, epigenetic, environmental, etc. We want to provide a platform for sharing new developments and strategies in slowing the process of ageing and extending lifespan. Furthermore, we would like to focus on longevity medicine and interventions that prolong human healthspan.

Prof. Dr. Mateusz Mołoń
Dr. Milena Georgieva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ageing
• antiageing interventions
• senolytic drugs
• stem cells
• gene editing
• regenerative medicine
• longevity medicine
• nanomedicine
• lifestyle interventions
• gerontology